Coming therapies: Abacavir

International Journal of Clinical Practice, Supplement

Volumn , Issue 103, 1999, Pages 35-38

  Staszewski, Schlomo ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ABDOMINAL PAIN; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG BIOAVAILABILITY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG POTENCY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LIVER DYSFUNCTION; LYMPHOCYTOPENIA; MALAISE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VERTIGO; VIRUS LOAD; VOMITING; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTI-HIV AGENTS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DIDEOXYNUCLEOSIDES; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; LAMIVUDINE; RANDOMIZED CONTROLLED TRIALS; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

EID: 33749214324     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (11)

1. Daluge SM, Good SS, Palette MB et al. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother 1997; 41: 1082-1093.
2. Ravitch JR, Walsh JS, Reese MJ et al. In vivo, and in vitro studies of the potential for drug interactions involving the antiretroviral abacavir (1592) in humans. (Poster 634). 5th Conference on Retroviruses and Opportunistic Infections, Chicago 1998.
3. Saag MS, Sonnerborg A, Torres RA et al. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. AIDS 1998; 12: F203-F209.
4. Lanier ER, Stone C, Griffin P et al. Phenotypic sensitivity to 1592 (abacavir) in the presence of multiple genotypic mutations: correlation with viral load response. (Abstract 686) 5th Conference on Retroviruses and Opportunistic Infections, Chicago 1998.
5. Mellors JW, Hertogs K, Peelers F et al. Susceptibility profile (Antivirogram™) of 943 clinical HIV-1 isolates to abacavir (1592U89). (Poster 687) 5th Conference on Retroviruses and Opportunistic Infections, Chicago 1998.
6. Staszewski S, Katlama C, Harrer T et al. Abacavir (1592, ABC) in protocol CNAB 2002, provides effective long-term 72 week ART for patients on triple therapy regimens. (Abstract 12212) 12th World AIDS Conference, Geneva 1998.
7. Fischl M, Greenberg S, Clumeck N et al. Ziagen (abacavir, ABC, 1592) combined with 3TC and AZT is highly effective through 48 weeks in HIV-1 infected antiretroviral-therapy-naïve subjects (CNAA 3003). (Abstract 19) 6th Conference on Retroviruses and Opportunistic Infections, Chicago 1999.
8. Staszewski S, Keiser P, Qathe J et al. Ziagen/Combivir is equivalent to indinavir/ combivir in antiretroviral naïve adults at 24 weeks (CAN 3005). (Abstract 20) 6th Conference on Retroviruses and Opportunistic Infections, Chicago 1999.
9. Tashima K, Staszewski S, Stryker R et al. A Phase III, multicenter, randomized, open-label study to compare the antiretroviral activity and tolerability of efavirenz (SUSTIVA™, EFV) + indinavir (IDV) versus EFV + zidovudine (AZT)+ lamivudine (3TC), versus EFV+IDV+AZT at 48 weeks (Study DMP 266-006). (Poster LB-16) 6th Conference on Retroviruses and Opportunistic Infections, Chicago 1999.
10. Mellors J, Lederman M, Haas D et al. Durable activity of Ziagen combined with protease inhibitors in therapy naïve adults. (Abstract 625) 6th Conference on Retroviruses and Opportunistic Infections, Chicago 1999.
11. Bart P-A, Rizzard GP, Gallant S et al. Combination Ziagen/amprenavir (141, APV-USAN) therapy in HIV-1 infected antiretroviral naïve subjects with CD4+ counts >400 cells/ml and plasma HIV-1 RNA >5000 copies/ml. (Abstract 626) 6th Conference on Retroviruses and Opportunistic Infections, Chicago 1999.